HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Willis, M. S. Articles by Lugo, A. M. Search for Related Content PubMed PubMed Citation Articles by Willis, M. S. Articles by Lugo, A. M.

MINA S. WILLIS, PHARM.D., BCPS, PA-C, is Clinical Pharmacy Specialist, Internal Medicine, Department of Pharmacy, National Naval Medical Center, Bethesda, MD. AMY M. LUGO, PHARM.D., BCPS, BC-ADM, is Assistant Professor, Department of Pharmacy Practice, South University School of Pharmacy, Savannah, GA.

Address correspondence to Dr. Willis at the Department of Pharmacy, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889 (mina.willis{at}med.navy.mil).

Purpose. A case of amiodarone-induced neurotoxicity is reported. Summary. A 76-year-old man arrivedat the emergency department with complaints of increasing imbalance over the past 2.5 months after a recent discharge from the hospital. He reported that his balance had worsened over the past week and that he now must use a cane to walk. His medical history included coronary artery disease, peripheral vascular disease, hypertension, hyperlipidemia, and paroxysmal atrial fibrillation. Home medications included enteric-coated aspirin 325 mg orally daily, isosorbide dinitrate 20 mg orally twice daily, amiodarone hydrochloride 400 mg orally three times daily, hydralazine hydrochloride 10 mg orally four times daily, extended-release metoprolol succinate 142.5 mg (equivalent to metoprolol tartrate 150 mg) orally daily, simvastatin 80 mg orally daily, and warfarin sodium 2.5 mg orally daily. Physical examination of the patient revealed finger-to-nose dysmetria, unsteady gait with leftward prevalence, positive Romberg’s sign, and inability to perform heel-to-toe walk. All radiographic imaging studies and laboratory test values ruled out acute pathologies, bleeding, masses, and ischemia. As there were no physiological findings for the patient’s symptoms and after careful evaluation of the patient’s drug regimen, the patient’s amiodarone was discontinued. His ataxia began to slowly improve. All neurologic symptoms resolved completely five months after discontinuation of amiodarone. Conclusion. A 76-year-old man developed ataxia after taking amiodarone hydrochloride 400 mg orally three times daily for more than two months; the regimen was the intended loading dosage. The ataxia lessened over the first two weeks after the amiodarone was discontinued and resolved completely within five months after drug discontinuation. Index terms: Amiodarone; Aspirin; Cardiac drugs; Hydralazine; Isosorbide dinitrate; Metoprolol; Neurotoxicity syndromes; Simvastatin; Toxicity; Warfarin